1.
Trends Biotechnol
; 41(3): 281-282, 2023 03.
Article
in English
| MEDLINE | ID: covidwho-2165900
ABSTRACT
The unprecedented rapid deployment of mRNA vaccines against COVID-19 can be traced back to the early studies of RNA nanocarriers, including the study by Zimmermann et al. which showcased the effectiveness of RNA nanocarriers in vivo. This study, among others, ultimately resulted in Onpattro, the first FDA-approved RNA formulation.